Oruka Therapeutics Aktie
WKN DE: A3DPH3 / ISIN: US6876041087
17.09.2025 07:47:22
|
Oruka Therapeutics Reports Positive Interim Data From Phase 1 Study Of ORKA-001
(RTTNews) - Oruka Therapeutics, Inc. (ORKA) Tuesday announced positive interim data from its Phase 1 study evaluating the safety and pharmacokinetics of ORKA-001 in healthy volunteers.
ORKA-001, a long-acting monoclonal antibody targeting IL-23p19, is being investigated for the treatment of patients with Psoriasis.
In the Phase 1 study, ORKA-001 demonstrated an estimated half-life of about 100 days, suggesting the potential for once-yearly dosing, and was well tolerated with a favorable safety profile.
Initial data from the ongoing EVERLAST-A Phase 2a study are expected in the second half of 2026. Oruka also expects to initiate a Phase 2b study of ORKA-001 in patients with plaque psoriasis, dubbed EVERLAST-B, in the first half of 2026.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Oruka Therapeutics Inc Registered Shsmehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu Oruka Therapeutics Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
Oruka Therapeutics Inc Registered Shs | 15,90 | 1,27% |
|